Details for Patent: 7,832,351
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 7,832,351 protect, and when does it expire?
Patent 7,832,351 protects ADVAIR HFA, FLOVENT HFA, and VENTOLIN HFA, and is included in three NDAs.
Protection for ADVAIR HFA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has twenty-nine patent family members in seventeen countries.
Summary for Patent: 7,832,351
Title: | Actuation indicator for a dispensing device |
Abstract: | An actuation indicator which includes a drums sub-assembly including a rotatable actuation indicator wheel, a rocking ratchet pawl for rotating the indicator wheel in a set direction and a rocking mechanism for the pawl driven by a slipping clutch arrangement, wherein the slipping clutch arrangement includes a slipping clutch spring engaged at one end to a pinion of a rack and pinion assembly and at a second end to the ratchet pawl is described. |
Inventor(s): | Bonney; Stanley George (Ware, GB), Brand; Peter John (Ware, GB), Godfrey; James William (Ware, GB), Rand; Paul Kenneth (Ware, GB) |
Assignee: | Glaxo Group Limited (Greenford, Middlesex, GB) |
Application Number: | 12/333,420 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,832,351 |
Patent Claim Types: see list of patent claims | Device; Delivery; |
Drugs Protected by US Patent 7,832,351
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxo Grp Ltd | ADVAIR HFA | fluticasone propionate; salmeterol xinafoate | AEROSOL, METERED;INHALATION | 021254-001 | Jun 8, 2006 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
Glaxo Grp Ltd | ADVAIR HFA | fluticasone propionate; salmeterol xinafoate | AEROSOL, METERED;INHALATION | 021254-002 | Jun 8, 2006 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
Glaxo Grp Ltd | ADVAIR HFA | fluticasone propionate; salmeterol xinafoate | AEROSOL, METERED;INHALATION | 021254-003 | Jun 8, 2006 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,832,351
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 424010 | See Plans and Pricing | |||
Australia | 2003278236 | See Plans and Pricing | |||
Brazil | 0311557 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |